Data / Form D filings / Sage Therapeutics, Inc.
Sage Therapeutics, Inc.: Form D filings
Sage Therapeutics, Inc., a pharmaceuticals company in Cambridge, MA, filed 3 Form D notices with the SEC between 2014 and 2021. The latest, on January 15, 2021, reports $650 million sold of a $650 million offering to 1 investor.
Find out what Sage Therapeutics, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 215 FIRST STREET, Cambridge, MA, 02142
- Phone
- (617) 299-8380
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1597553
The full lists. Form D filings in Massachusetts: 1,533 rows, $76.65, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 15, 2021 | New notice | $649,986,998 | $649,986,998 | $0 | 1 | Dec 31, 2020 | sec.gov |
| Mar 24, 2014 | New notice | $38,000,000 | $38,000,000 | $0 | 15 | Mar 11, 2014 | sec.gov |
| Jan 21, 2014 | New notice | $20,000,000 | $10,000,000 | $10,000,000 | 3 | Jan 7, 2014 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Barry Greene | Executive Officer, Director | |
| Kimi Iguchi | Executive Officer | |
| Michael Cloonan | Executive Officer | |
| Anne Marie Cook | Executive Officer | |
| Stephen J. Kanes | Executive Officer | |
| Albert J. Robichaud | Executive Officer | |
| Jeffrey M. Jonas | Executive Officer, Director | |
| Elizabeth F. Barrett | Director | |
| James F. Frates | Director | |
| Geno F. Germano | Director | |
| George F. Golumbeski | Director | |
| Steven F. Paul | Director | |
| Kevin P. Starr | Director | |
| Michael F. Cola | Director |
Other pharmaceuticals companies in Massachusetts that filed recently
- BridgeHealth Pharmaceuticals, Inc. $3.5 million · Nov 5, 2026
- Land Therapeutics Inc. $17.5 million · Oct 21, 2026
- Crosslink Therapeutics Inc. $5.5 million · Oct 20, 2026
- Sentonix, Inc. $12.7 million · Aug 20, 2026
Every Form D from the week of Jan 11, 2021 · All recent filings in Massachusetts · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Sage Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.